Measurable ImpactScientists at Regina Elena National Cancer Institute (RENCI) say that the breast cancer drug Aromasin has a measurable impact on cells of mesothelioma: an ultra-aggressive cancer caused by the inhalation of fibrous asbestos.
Published in the Molecular Cancer journal, RENCI's lead researcher Barbara Nuvoli said: "We [have shown] a significant reduction of cell proliferation, survival, migration and block of cells in S phase of cell cycle in mesothelioma cells upon exemestane (Aromasin) treatment."
Lab SuccessesIn combination with Alimta, an acknowledged mesothelioma drug, Aromasin was used to treat small mammals which had been infected in the lab with the cancer. By the conclusion of the treatment, scientists were unable to isolate sufficient samples of mesothelioma tumour to feasibly test.
Drug Already ApprovedAccording to the editor of the influential journal Surviving Mesothelioma, Alex Strauss, among the most promising aspects of the study is its focus on a treatment already approved by the US Food and Drug Administration.
Boost for Mesothelioma Patients?"If further studies show Aromasin can help mesothelioma patients, it could be available to them much sooner than an experimental drug might be".
Aromasin fights cancer by blocking an oestrogen-producing enzyme. The drug is also licensed for treating breast cancer in the UK.